| name | es-gh-treatment-offer |
| description | This skill determines whether growth hormone therapy should be initiated in childhood cancer survivors with confirmed growth hormone deficiency, based on demonstrated safety and efficacy in this population. Triggers include clinician questions such as "Should I start GH therapy for confirmed GHD?" or "Is growth hormone appropriate for this survivor with documented deficiency?" |
Indicate growth hormone therapy for confirmed GHD
STEP 1 — Gather Information
Confirm growth hormone deficiency via provocative testing (insulin tolerance test, glucagon, or arginine) per guideline, avoiding reliance on serum IGF‑I alone; document cancer treatment details (HP axis radiation dose, TBI, spinal radiation), assess for other pituitary hormone deficiencies, verify disease‑free status (≥1 year off therapy) or note stable disease, and review current medications (e.g., tyrosine kinase inhibitors).
Action: If GHD is confirmed by appropriate provocative testing and not solely by IGF‑I, proceed to Step 2; otherwise, do not offer GH.
STEP 2 — Rule In / Rule Out
Rule out active malignancy unless the patient has been disease‑free for ≥1 year or has stable disease discussed with an oncologist; rule out concurrent tyrosine kinase inhibitor therapy (suggest against GH); rule out uncorrected central hypothyroidism or adrenal insufficiency as prerequisites.
Action: If no contraindications are present, proceed to Step 3; otherwise, do not offer GH.
STEP 3 — Classify or Stratify
Classify the patient as a candidate for GH when GHD is confirmed, disease‑free ≥1 year (or stable disease with oncologist discussion), and no contraindications from Step 2 exist.
Action: Proceed to Step 4 to decide on GH offering.
STEP 4 — Decide
Offer growth hormone therapy using regimens similar to those for non‑cancer‑population GHD, initiate after confirming baseline assessments (thyroid, adrenal, IGF‑I), and schedule monitoring per guideline.
Action: Initiate GH therapy.
Clinical Guardrails / Mimics / Pitfalls
Monitor serum IGF‑I to keep within age‑ and sex‑specific normal range; assess for slipped capital femoral epiphysis, metabolic changes, and intracranial hypertension; avoid GH in patients on active tyrosine kinase inhibitors; consider reduced spinal growth benefit after spinal radiation; discuss timing with oncologist for patients with stable disease; ensure adequate thyroid and adrenal function before starting GH; do not rely on spontaneous GH secretion or GHRH‑arginine alone for diagnosis.
Concrete Clinical Example
A 12‑year‑old survivor of medulloblastoma treated with cranial radiation 18 Gy is now 2 years off therapy, has confirmed GHD by insulin tolerance test (peak GH < 5 ng/mL), no other hormone deficits, and is disease‑free.
Decision: Offer GH therapy per standard regimen.
Source: Hypothalamic Pituitary and Growth Disorders in Survivors of Childhood Cancer, Sklar et al., Endocrine Society Clinical Practice Guideline, 2018, doi:10.1210/jc.2018-01175
